Skip to Content Skip to Navigation
27th February 2024 Cancer

$250,000 to advance treatments for lymphoma

Web lymphoma grants

The Hospital Research Foundation (THRF) Group is proud to announce $250,000 towards advancing treatments for lymphoma.

Lymphoma is a cancer within the lymphatic system, affecting your immune cells and often with painful symptoms in the neck, armpits or groin.

In Australia, lymphomas are:

  • The most common cancer in people aged 15-29 years
  • The third most common cancer in children aged 0-14 years
  • The sixth most common cancer in adults.

Two research grants have been awarded, focusing on less invasive and more personalised treatments to improve and save lives.

“The incidence of lymphomas in Australia has increased over the past 20 years and is continuing to trend upwards. This is a scary reality Australians are facing and these two grants have the potential to be life-changing for those fighting lymphoma,” THRF Group CEO Paul Flynn said.

The projects include:

Professor Stuart Pitson – New therapy for aggressive non-Hodgkin lymphoma
University of South Australia | Centre for Cancer Biology

Aggressive non-Hodgkin lymphoma (aNHL) can lead to poor outcomes for patients, in particular those who don’t respond well to treatment or experience a relapse.

New therapies are needed for these patients, and Prof Pitson and his team are developing an advanced, more targeted treatment focussing on a specific enzyme which he hopes will lead to a new treatment for aNHL.

Dr Giles Best – Targeted treatment for diffuse large B-cell lymphoma
Flinders University

Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will relapse or experience significant side effects following current therapies, highlighting the urgent need for better, more targeted treatments.

This project will enable Dr Best to continue preliminary studies into a drug that has shown to kill DLBCL cells, which could potentially lead to a new treatment and save more lives.

Thank you to our donors, fundraisers, partners and ticket buyers in The Hospital Research Foundation Home Lottery who make it possible to support these critical projects with the potential of saving lives.

We look forward to updating you on their progress.

Donate